These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 18626480)

  • 1. Langerhans cell dogma: another round of rejections.
    Udey MC; Rosenberg AS
    J Invest Dermatol; 2008 Aug; 128(8):1881-3. PubMed ID: 18626480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Langerhans cells are not required for efficient skin graft rejection.
    Obhrai JS; Oberbarnscheidt M; Zhang N; Mueller DL; Shlomchik WD; Lakkis FG; Shlomchik MJ; Kaplan DH
    J Invest Dermatol; 2008 Aug; 128(8):1950-5. PubMed ID: 18337832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting of the hNC16A collagen domain to dendritic cells induces tolerance to human type XVII collagen.
    Ettinger M; Gratz IK; Gruber C; Hauser-Kronberger C; Johnson TS; Mahnke K; Thalhamer J; Hintner H; Peckl-Schmid D; Bauer JW
    Exp Dermatol; 2012 May; 21(5):395-8. PubMed ID: 22509840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of IA antigen+ epidermal cells in rejection of rat skin equivalent grafts.
    Lerner-Tung MB; Hull BE
    Transplantation; 1990 Jun; 49(6):1181-4. PubMed ID: 2163135
    [No Abstract]   [Full Text] [Related]  

  • 5. Human epidermal Langerhans cells replenish skin xenografts and are depleted by alloreactive T cells in vivo.
    Hemmerling J; Wegner-Kops J; von Stebut E; Wolff D; Wagner EM; Hartwig UF; André MC; Theobald M; Schopf RE; Herr W; Meyer RG
    J Immunol; 2011 Aug; 187(3):1142-9. PubMed ID: 21697461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skin allografts--lymph veiled (dendritic) cells are responsible for initiation of rejection in canine skin/SCID mouse chimera model.
    Galkowska H; Olszewski WL; Moscicka M; Cybulska E; Ziolkowska A; Wojewodzka U; Mijal J
    Ann Transplant; 1999; 4(3-4):5-10. PubMed ID: 10853773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A paradigm shift in the mechanisms of graft rejection.
    Zell D; Hu S; Kirsner RS
    J Invest Dermatol; 2008 Aug; 128(8):1874. PubMed ID: 18626477
    [No Abstract]   [Full Text] [Related]  

  • 8. Cultured epithelium allografts: Langerhans cell and Thy-1+ dendritic epidermal cell depletion effects on allograft rejection.
    Rouabhia M; Germain L; Bélanger F; Auger FA
    Transplantation; 1993 Aug; 56(2):259-64. PubMed ID: 8102819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo models of inflammation: immune rejection and skin transplantation in vivo.
    Binet I; Wood KJ
    Methods Mol Biol; 2003; 225():239-48. PubMed ID: 12769492
    [No Abstract]   [Full Text] [Related]  

  • 10. Presentation of the HPV16E7 protein by skin grafts is insufficient to allow graft rejection in an E7-primed animal.
    Dunn LA; Evander M; Tindle RW; Bulloch AL; de Kluyver RL; Fernando GJ; Lambert PF; Frazer IH
    Virology; 1997 Aug; 235(1):94-103. PubMed ID: 9300040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carcinogen-treated skin allografts rejected by T lymphocytes specific for class I but not class II MHC antigens.
    Halliday GM; Odling KA; Muller HK
    Cell Immunol; 1993 Oct; 151(2):291-9. PubMed ID: 8402936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depletion of cells of monocyte lineage prevents loss of renal microvasculature in murine kidney transplantation.
    Qi F; Adair A; Ferenbach D; Vass DG; Mylonas KJ; Kipari T; Clay M; Kluth DC; Hughes J; Marson LP
    Transplantation; 2008 Nov; 86(9):1267-74. PubMed ID: 19005409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: association with prolonged allograft survival.
    Lan YY; Tokita D; Wang Z; Wang HC; Zhan J; Brinkmann V; Thomson AW
    Transpl Immunol; 2008 Nov; 20(1-2):88-94. PubMed ID: 18694829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pillars article: long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature. 1996. 381: 434-438. 1996.
    Larsen CP; Elwood ET; Alexander DZ; Ritchie SC; Hendrix R; Tucker-Burden C; Cho HR; Aruffo A; Hollenbaugh D; Linsley PS; Winn KJ; Pearson TC
    J Immunol; 2011 Mar; 186(5):2693-7. PubMed ID: 21325218
    [No Abstract]   [Full Text] [Related]  

  • 15. Rejection of skin allografts by CD4+ T cells is antigen-specific and requires expression of target alloantigen on Ia- epidermal cells.
    Rosenberg AS; Katz SI; Singer A
    J Immunol; 1989 Oct; 143(8):2452-6. PubMed ID: 2477443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human CD4+ T cells mediate rejection of porcine xenografts.
    Friedman T; Shimizu A; Smith RN; Colvin RB; Seebach JD; Sachs DH; Iacomini J
    J Immunol; 1999 May; 162(9):5256-62. PubMed ID: 10228000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction.
    Rosenberg AS; Singer A
    Annu Rev Immunol; 1992; 10():333-58. PubMed ID: 1590990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-5 mediates eosinophilic rejection of MHC class II-disparate skin allografts in mice.
    Le Moine A; Surquin M; Demoor FX; Noël JC; Nahori MA; Pretolani M; Flamand V; Braun MY; Goldman M; Abramowicz D
    J Immunol; 1999 Oct; 163(7):3778-84. PubMed ID: 10490975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclosporine combined with nonlytic interleukin 2/Fc fusion protein improves immune response to hepatitis B vaccination in a mouse skin transplantation model.
    Li Z; Zhang D; Gao J; Li WX; Zhu JY
    Transplant Proc; 2013; 45(6):2559-64. PubMed ID: 23953581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A depression technique of the epidermal Langerhans cell in cadaver split skin.
    Alsbjörn B
    Scand J Plast Reconstr Surg; 1984; 18(1):61-4. PubMed ID: 6377485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.